2021 American Society of Hematology Annual Meeting*

In this phase I trial update, cevostamab continued to demonstrate clinical activity and a safety profile that supports additional development; double step-up dosing in cycle 1 appeared to mitigate some risk of cytokine release syndrome.

The novel bispecific antibody talquetamab appears active and tolerable in heavily pretreated patients with relapsed/refractory multiple myeloma.

Updated results from a first-in-human study of REGN5458, a BCMA x CD3 bispecific, shows early, deep, and durable responses in patients with heavily pretreated R/R MM.

Results from dose-expansion cohort of iberdomide with dexamethasone showing clinically meaningful and durable responses in heavily pretreated R/R MM, including 97% being triple-class refractory.

Belantamab mafodotin appears to be safe, with a manageable ocular safety profile, when given with lenalidomide and dexamethasone in transplant-ineligible NDMM.

The safety profile of belantamab mafodotin plus VRd for patients with newly diagnosed MM who are not eligible for ASCT was similar to the known safety of single-agent belantamab mafodotin in patients with R/R MM.

Superior MRD negativity rates were achieved after induction with isatuximab + VRd vs VRd alone in patients with newly diagnosed multiple myeloma.

The addition of ixazomib to lenalidomide/dexamethasone maintenance did not confer a PFS benefit in any subgroup of patients following the completion of ASCT, likely due to dose reductions/discontinuation associated with toxicity.

A median of ~2 years of follow-up of the CARTITUDE-1 trial showed durable and deepening responses with cilta-cel in patents with relapsed/refractory multiple myeloma.

After 24 months of maintenance therapy, D-VRd continued to show deep and durable responses in transplant-eligible patients with ND MM.

In patients with t(11;14) R/R MM, venetoclax/daratumumab/dexamethasone appears safe with promising efficacy vs bortezomib/daratumumab/dexamethasone.

MCARH109 demonstrated a promising safety profile with high rates of clinical response in patients with heavily pretreated R/R MM, including those who relapsed post BCMA-targeted CAR T-cell therapy.

Venetoclax added to bortezomib/dexamethasone improved PFS in patients with relapsed/refractory multiple myeloma and t(11;14) but resulted in increased mortality in the overall patient population.

Teclistamab showed promising efficacy of 62% ORR with favorable tolerability in patients with triple-class–exposed R/R MM.

Investigational BCMA-targeted bispecific antibody ABBV-383 continues to be well tolerated with promising activity in patients with R/R MM.